About
Our delegates say it best: This is the “Best pricing conference in existence” Jessi Gottlieb, Counsel, Hoffmann LaRoche
As the premier legal and regulatory pricing and reimbursement event that for the past 7 years, this is the only conference that allows you to see the complete pricing and reimbursement picture. This seventh annual program gives full coverage of all the new developments from the leading industry experts, including in-house pricing experts and a regular stellar faculty of government enforcers.
With changes to AMP, increased transparency and the uncertainty of AWP's future, the time is critical to have a comprehensive pricing strategy in place. To ensure your rebate reimbursement exposure is limited, that you are being adequately reimbursed for drugs provided to beneficiaries or that pricing for government programs is not negatively affecting commercial prices, you need to understand the changes that are taking place and devise a strategy to deal with them.
Nearly every major component of the pharmaceutical industry, as well as public and private healthcare, is in a tailspin. R&D, IP, product and formulary placement, and patient access all have been touched by these reforms in some way. These newest reforms are at the root of new and continuing anxieties over pricing transparency and fraud and abuse. They also exacerbate the scope of existing dilemmas, such as public and private pricing litigation and criminal enforcement actions.
Designed especially for Pharma/Biotech in-house counsel, officers, directors, managers, you will come away from this event able to:
- Make sense of all new laws and regulations affecting drug pricing and reimbursement
- Recognize new pricing and reimbursement risks and hotspots
- Benefit from the insights and knowledge of pricing and reimbursement experts
- Update compliance programs and business strategies to account for evolving laws
- Chart the course of pricing and reimbursement in relation to the changing role of government payor programs and the evolution of American healthcare
About
Our delegates say it best: This is the “Best pricing conference in existence” Jessi Gottlieb, Counsel, Hoffmann LaRoche
As the premier legal and regulatory pricing and reimbursement event that for the past 7 years, this is the only conference that allows you to see the complete pricing and reimbursement picture. This seventh annual program gives full coverage of all the new developments from the leading industry experts, including in-house pricing experts and a regular stellar faculty of government enforcers.
With changes to AMP, increased transparency and the uncertainty of AWP's future, the time is critical to have a comprehensive pricing strategy in place. To ensure your rebate reimbursement exposure is limited, that you are being adequately reimbursed for drugs provided to beneficiaries or that pricing for government programs is not negatively affecting commercial prices, you need to understand the changes that are taking place and devise a strategy to deal with them.
Nearly every major component of the pharmaceutical industry, as well as public and private healthcare, is in a tailspin. R&D, IP, product and formulary placement, and patient access all have been touched by these reforms in some way. These newest reforms are at the root of new and continuing anxieties over pricing transparency and fraud and abuse. They also exacerbate the scope of existing dilemmas, such as public and private pricing litigation and criminal enforcement actions.
Designed especially for Pharma/Biotech in-house counsel, officers, directors, managers, you will come away from this event able to:
- Make sense of all new laws and regulations affecting drug pricing and reimbursement
- Recognize new pricing and reimbursement risks and hotspots
- Benefit from the insights and knowledge of pricing and reimbursement experts
- Update compliance programs and business strategies to account for evolving laws
- Chart the course of pricing and reimbursement in relation to the changing role of government payor programs and the evolution of American healthcare
Contents & Contributors
Preparing for Potential Changes to AMP and Examining How Those Changes Will Affect the Pricing Sector
Don L. Bell, II, Senior Vice President and General Counsel, National Association of Chain Drug Stores (Alexandria, VA)
Benjamin S. Martin, Attorney, Epstein Becker & Green, P.C. (Washington, DC)
Navigating Compliance Obligations Under New TRICARE Regulations
Howard Crawford, CPT, USAFR, MSC, (Ret.), Federal Account Manager, Genentech, Inc. (Washington, DC)
Constance A. Wilkinson, Partner, Epstein Becker & Green, P.C. (Washington, DC)
Resolving Disputes with State Medicaid Programs and CMS
Edith S. Marshall, Counsel, Arnold & Porter LLP (Washington, DC)
Tracking the Evolution of MDL 1456
William F. Cavanaugh, Jr., Partner, Patterson Belknap Webb & Tyler LLP, (New York, NY)
Blakely J. Pryor, Attorney, Shook, Hardy & Bacon L.L.P. (Kansas City, MO)
Tina M. Tabacchi, Partner, Jones Day (Chicago, IL)
Mastering the Mechanics and Operational Challenges Associated With the Final DRA Rule
Timothy J. Nugent, Managing Director, FTI Consulting (New York, NY)
Larri A. Short, Partner, Arent Fox LLP (Washington, DC)
Countering Evolving Theories of Liability in AWP Cases
C. Michael Moore, Partner, Sonnenschein Nath & Rosenthal LLP (Dallas, TX)
D. Jacques Smith, Partner, Arent Fox LLP (Washington, DC)
Negative Pricing: When Statutory Discounts Create a Profit Center for Government Programs
Meghan Davis, Director, Huron Consulting Group, LLC (New York, NY)
Curtis Moore, Associate Director of Health Outcomes and Strategic Pricing, Genzyme (Cambridge, MA)
John D. Shakow, Partner, King & Spalding (Washington, DC)
Grappling With The Uncertain Future of AWP: Preparing For the Changing Reimbursement Landscape
Christopher Stomberg, Ph.D., Partner, Bates White, LLC (Washington, DC)
Lyndon M. Tretter, Partner, Hogan & Hartson LLP (New York, NY)
Creating a Robust Pricing Compliance/Audit Program That Will Provide the Most Accurate Calculations and the Ability to Verify Them
Dennis K. Barnes, JD, CPA, Director, Advisory Services, KPMG LLP (Philadelphia, PA)
Lena Robins, Partner, Foley & Lardner LLP (Washington, DC)
Publication Details